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Abstract
Purpose Trials of novel drugs used in advanced disease often show only progression-free survival or modest overall survival
benefits. Hypothetical studies suggest that stabilisation of metastatic disease and/or symptom burden are worth treatment-related
side effects. We examined this premise contemporaneously using qualitative and quantitative methods.
Methods Patients with metastatic cancers expected to live > 6 months and prescribed drugs aimed at cancer control
were interviewed: at baseline, at 6 weeks, at progression, and if treatment was stopped for toxicity. They also
completed Functional Assessment of Cancer Therapy (FACT-G) plus Anti-Angiogenesis (AA) subscale questionnaires
at baseline then monthly for 6 months.
Results Ninety out of 120 (75%) eligible patients participated: 41 (45%) remained on study for 6 months, 36 progressed or died, 4
had treatment breaks, and 9 withdrew due to toxicity. By 6 weeks, 66/69 (96%) patients were experiencing side effects which
impacted their activities. Low QoL scores at baseline did not predict a higher risk of death or dropout. At 6-week interviews, as the
side effect severity increased, patients were significantly less inclined to view the benefit of cancer control as worthwhile (X2 = 50.7,
P < 0.001). Emotional well-being initially improved from baseline by 10 weeks, then gradually returned to baseline levels.
Conclusion Maintaining QoL is vital to most patients with advanced cancer so minimising treatment-related side effects is
essential. As side effect severity increased, drugs that controlled cancer for short periods were not viewed as worthwhile.
Patients need to have the therapeutic aims of further anti-cancer treatment explained honestly and sensitively.
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Introduction
Demonstrating overall survival (OS) benefit is regarded as a
gold standard outcome in oncology trials, alongside improve-
ment of symptoms [1]. Progression-free survival (PFS) or time
to progression (TTP) are established if controversial surro-
gates for OS. Progression, as defined by an increase in tu-
mour(s) size on scans using RECIST criteria, was never orig-
inally intended to be utilised as a surrogate for survival [2].
Nevertheless, PFS is increasingly used as a primary outcome
measure in trials and for drug licencing approvals. The adop-
tion of PFS is attractive as studies can be shorter, require fewer
patients, and provide results faster [3]. A consequence is that
many patients with advanced/metastatic disease are prescribed
novel drugs that may have demonstrated only PFS improve-
ments or minimal OS benefits. A study of 68 oncology drug
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indications licenced by the European Medicines Agency
2009–2013 showed that only five had a beneficial effect on
Quality of Life (QoL) at the time of licencing [4]. There are
scanty data and therefore uncertainty as to whether or not
treatments exerting a marginal impact on length of life also
improve its quality. Evenwhen patient-reported outcomemea-
sures (PROMs) are included in clinical trials of novel thera-
pies, they are not always chosen carefully enough to include
items likely to impact on quality of life. Data may not be
collected at appropriate time points, and analyses are rarely
integrated with other study outcomes that would enable better
understanding of genuine patient-derived benefits [5]. Recent
recommendations supplementing existing guidelines on ad-
verse event (AE) reporting have suggested the inclusion of
outcomes more relevant to clinicians and patients thereby fa-
cilitating more candid shared decision-making [6].
Recommendations include expressing AEs that impact QoL
in terms of their severity, frequency, and duration, and the
avoidance of vague phrases that describe drugs as ‘safe and
well tolerated’.
It is important to understand more about the putative
benefits of PFS from a patient perspective [7], in par-
ticular to determine if stabilisation of metastatic disease
and/or a reduction in the burden of disease symptoms
justifies treatment side effects [3, 8]. Baseline data from
the AVALPROFS (Assessing the ‘VALue’ to patients of
PROgression Free Survival) study focused on the con-
cordance between oncologists and patients about likely
benefits, understanding of therapeutic aims, and expec-
tations of treatment [9]. Results showed oncologists
were generally more optimistic about the likely benefits
of treatment compared with published data from clinical
trials and expected 62% of patients to live longer with
treatment than without it. Only 52% mentioned pallia-
tive care as an option despite increasing evidence that
early referral may improve QoL and increase survival
[10, 11]. The majority of patients (57%) had ‘no idea’
or were unclear what PFS meant, and 50% believed
extension of life to be the primary therapeutic aim.
Many of those who recognised that treatment intent
was to slow or stop cancer growing, mistakenly thought
this meant living longer [9].
Some have questioned whether merely delaying pro-
gression without increasing survival time in metastatic
disease is even a worthy goal [2]. It seems intuitively
reasonable that arresting a tumour’s growth would bring
relief and enhance psychological well-being. Conversely,
a lack of response to treatment might increase anxiety
but few data support these assertions. Furthermore, there
have been no contemporaneous rather than hypothetical
studies conducted in this area.
We report here further results fromAVALPROFS regarding
the non-monetary ‘value’ that patients with advanced disease
place on the drugs they received; specifically, how long they
would require treatment to continue controlling the cancer to
make it worthwhile and illustrate the impact treatment-related
side effects and disease progression had on QoL and emotion-
al well-being.
Methods
Study design and participants
Participants were recruited between March 2014 and July
2015 from 11 UK cancer centres by members of the clinical
team. Oncologists briefly introduced the study to their patients
who completed expression of interest forms providing contact
details and took study information sheets home to read.
Independent researchers followed up approximately 24 h later
to organise consent and interview dates. The project was ap-
proved by London-Surrey Borders Research Ethics
Committee (Ref: 14/LO/0045).
Eligibility criteria
Patients aware of their diagnosis, able to be interviewed in
English, with a predicted life expectancy of ≥ 6 months, and
who were prescribed drugs with PFS or modest (1–3 months)
OS benefits were eligible to join the study.
Assessment measures
Following consultations, during which treatment and care
options were discussed, oncologists completed checklists
probing information they had provided. The checklist
established diagnosis, stage of disease, sites of metastases,
treatments received to date, and drugs discussed at recent
consultations.
Comprehensive patient interview schedules were devel-
oped with members of Independent Cancer Patients' Voice
(ICPV), a patient involvement charity. Experienced re-
searchers interviewed patients either face-to-face at home
or by telephone if preferred at baseline (within 2 weeks of
the consultation), at 6 weeks later, and then at progression
or if treatment was stopped due to toxicity. Patients de-
scribed their understanding of the aims of treatment, side
effects experienced, and how they managed them. They
graded their most bothersome side effect using abridged
descriptions from the Common Toxicity Criteria of
Adverse Events (CTCAE) manual (Appendix 1). If not
currently experiencing side effects, they indicated what
would be their most bothersome side effect. Time trade-
off-type questions explored how worthwhile treatment
was or would be. Specifically, patients were asked as side
effect severity increased how long they would require the
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drugs to continue controlling cancer to make that treat-
ment worthwhile.
Additionally, patients completed QoL questionnaires:
Functional Assessment of Cancer Therapy (FACT-G) [12]
and the FACT-Anti-Angiogenesis (AA) subscale which con-
tains side effects pertinent to the cancer drugs prescribed even
those without anti-angiogenic modes of action [13]. FACT
questionnaires were administered prior to the first and second
interviews (6 weeks) and then at 10, 14, 18, and 22 weeks
either by post or completed by telephone according to pa-
tients’ preferences. Written consent was obtained prior to the
first interview.
This paper focuses on:
1) Views patients had about their treatments and side effects
2) The length of time patients would require treatment to
continue controlling the cancer if the severity of their
most bothersome side effect that they were experiencing
increased
3) Analyses of the QoL outcomes that examine predictive
factors and the relationship with treatment toxicity and
disease progression, illustrating specifically the impact
treatment-related side effects have on QoL and emotional
well-being
Statistical methods
The interview probes produced categorical data showing
proportions of patients who (a) agreed that the
treatment-related side effects were worth the benefit of
the new treatment and (b) the amount of additional time
required for the drug to control the cancer, as the side
effect severity increased. Data were examined at base-
line and at 6 weeks using chi-square statistics from cu-
mulative logistic ordinal regression analyses [14].
QoL across time was measured using the 27-item
FACT-G that comprises four subscales: physical (PWB),
functional (FWB), emotional (EWB), and social (SWB)
well-being; scores range from 0 to 108. Anti-A scores
range from 0 to 96. Mean total FACT subscale scores
were calculated at each time point. A trial outcome index
(TOI) PWB + FWB + AA subscale (range 0–148) was
also calculated. Observed and estimated mean plots were
produced over the six study time points. Multivariate lin-
ear regression analyses examined factors related to FACT-
G and TOI, adjusted for dropout [15]. Some additional
details of these analyses are given in Appendix 2. Also,
time-to-event analyses using Cox’s relative risk regression
model [16] were used to examine the relationship between
QoL measures and adverse events. Additionally, QoL was
examined based on the groups who stayed on study or
withdrew due to progression/death or toxicity.
Findings
Recruitment
Thirty-two oncologists from cancer centres across the UK
referred 120 patients with advanced heterogeneous cancers
to the study: 27 declined to participate and 3 proved ineligible,
75% (90/120) participated. The largest tumour group was lung
cancer (33%; 30/90). Although one entry criterion was a life
expectancy > 6 months, 40% (36/90) of patients died or
progressed during the 6-month study; 36% (13/36) before
the 6-week interview (see Fig. 1). Table 1 shows patients’
baseline demographic characteristics and drugs prescribed.
Patients’ views on side effects
Forty-three (48%) patients at baseline interview were within
2 weeks of starting new treatments, and 21% (9/43) said their
side effects (SEs) were worse than expected. At the 6-week
interview, a majority of patients (96%; 66/69) were experienc-
ing side effects, the most bothersome of which were fatigue
(33%), diarrhoea (17%), and skin rash (15%). These side ef-
fects affected the daily activities of most patients (88%; 58/
66), and almost a third (30%; 16/54) said hospital and medical
staff were unable to help. Themost common self-management
approaches used were rest (48%; 26/54) and change in diet
(19%; 10/54). Others used medications, creams, mouthwash,
and painkillers (48%; 26/54). The usefulness of these strate-
gies varied from very (56%; 30/54) to moderately (33%; 18/
54) or not at all (11%; 6/54).
Patients’ views at withdrawal of treatment
Table 2 shows some of the feelings expressed by patients who
had a treatment break (N = 4), who withdrew due to toxicity
(N = 9), or withdrew due to progression (N = 19). Those
whose treatment was stopped due to toxicity verbalised more
regret than those who stopped due to progression.
Views on the non-monetary Bvalue^ of treatment
Patients were asked to consider their most bothersome side
effect and then asked Bis (or would) the benefit of the drug in
terms of controlling the cancer be worth the following
grades of severity – yes, no, unsure.^ Patients read the mod-
ified CTCAE Grade descriptions for the relevant side effect
in ascending order starting at the lowest being experienced
or at grade I for patients who had not commenced treatment
(see Appendix 1). As the possible side effect severity in-
creased, overall patients were significantly less inclined to
feel that the benefit of controlling the cancer would be
worthwhile (ordinal regression global X2 = 73.35 on 2 df,
P < 0.0001) and this finding remained at the second
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Fig. 1 Consort diagram
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interview (X2 = 38.22 on 2 df, P < 0.0001). However, there
was little intra-patient variability over time; most patients
who considered, at baseline, a treatment as worthwhile at
a particular threshold, maintained their views at 6 weeks.
Notable exceptions were ten patients who at baseline did
not consider treatment as worthwhile if they were to de-
velop grade III side effects. They changed opinion at
6 weeks and did consider it worthwhile; seven of these
patients were coping with grade II side effects. In con-
trast, five patients who at baseline felt that treatment
would be worthwhile were they to develop grade III side
effects, did not think so at 6 weeks, three of whom were
experiencing grade II side effects.
For each grade of side effect, patients were asked Bhow
long do you require the treatment to continue to control the
cancer for you to consider it a worthwhile treatment for you?^
Response options were as follows: at least a month; 3, 6, and
12 months; and > a year. As the side effect severity profiles
increased from grades I to III, patients were more likely to
require the treatment to control the cancer for longer. This
relationship was significant at baseline (X2 = 9.35 on 2 df,
P = 0.009) and at 6 weeks (X2 = 7.34 on 2 df, P = 0.026).
(Table 3 shows the responses to the trade-off-type questions
at baseline and the 6-week interview.)
There was no difference in responses between the three
largest groups of patients, lung (N = 30), melanoma (N = 19),
and breast (N = 18). Table 4 shows some of the comments
made to explain patients’ choice; a proportion of patients
(N = 19/40) believed that 1 month of cancer control was
worthwhile even if they developed grade III side effects from
their treatment.
Quality of life
Attrition over time is usual in most studies of advanced metasta-
tic disease due to progression of disease or death. In
AVALPROFS, questionnaire completion dropped from 99%
(89/90) at baseline to 53% (48/90) by 22 weeks (see Fig. 1 for
reasons). In time to event analyses no relationship was demon-
strated between baseline QoL and dropout for any reason.
Supplementary Fig. 1a, b shows the overall observed means
and estimated means for the FACT-G and TOI respectively. The
latter are adjusted for dropout, and themost likely scenario is that
low scores are associated with a higher risk of death/dropout.
Adjusted means plot for the emotional well-being subscale
showed an improvement from baseline by 10 weeks, which
gradually returned to baseline levels (Supplementary Fig. 2).
Univariate linear regression analyses of the FACT-G and
TOI adjusted for dropout showed that in the TOI analyses,
lung cancer patients and then breast and other cancers had
the lowest scores (Supplementary Table 1). Also, scores were
lower in those diagnosed recently with metastatic disease and
for those whose diagnosis of advanced disease was > 2 years,
relative to those in the 1–2-year category. Multiple various
inhibitors and other treatments were associated with lower
scores while males had higher scores. These various factors
are highly correlated, and when all are included in a multivar-
iate regression model, the only significant effects are associ-
ated tumour site and time since diagnosis in the TOI analysis.
Examination of the longitudinal data subdivided by pa-
tients who stayed on study compared to those who
progressed/died, or experienced toxicity, showed the estimat-
ed means of the progression/died group lie below the toxicity
group, whereas for the observed means, it is the opposite.
Table 1 Patients’ characteristics and drugs prescribed
Characteristic N = 90
Sex
Male; female 39; 51
Age (years)
Mean (sd); range 65 (10.92); 32–85
Partner
Yes 58
Employed
Yes 27
Stage of disease
III 10
IV 80
Past treatments
Surgery 51
Chemotherapy 44
Radiotherapy 31
Hormone therapy 13
Treatment prescribed by tumour site
Lung (30) Afatinib (1)
Carboplatin + etoposide
(1) or gemcitabine (1)
Pemetrexed + carboplatin
(2) or cisplatin (2)
Erlotinib (23)
Melanoma (19) Ipilimumab (15)
Dabrafenib (2)
Vemurafenib (2)
Breast (18) Bevacizumab + paclitaxel (2)
Eribulin (6)
Everolimus + exemestane (5)
Trastuzumab emtansine TDM-1 (2)
Pertuzumab + docetaxel + trastuzumab (3)
Renal (10) Sunitinib (5)
Pazopanib (2)
Axitinib (2)
Everolimus (1)
Gynae (7) Bevacizumab (2) + carboplatin
+ paclitaxel (4) or + gemcitabine (1)
Head and neck (3) Cetuximab + cisplatin (2)
Cetuximab + carboplatin + 5FU (1)
Colorectal (2) Bevacizumab (1)
Bevacizumab + capecitabine (1)
Sarcoma (1) Pazopanib (1)
Site of metastasis
Lung 45
Bone 23
Liver 19
Brain 7
Lymph nodes 19
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Discussion
Most previous work in this area has relied on hypothetical data
collected from patients who are well. Retention of patients in
the AVALPROFS study was undoubtedly challenging; 19%
(17) of patients died (15 within 10 weeks) despite study eligi-
bility criteria of > 6-month survival. This suggests that over-
optimistic prognostication and prescribing led to ineffective
and quite toxic therapies being delivered to some patients.
Previous authors have commented that too many patients,
especially those with haematological malignancies and lung
cancer, are receiving anti-cancer treatments and experiencing
side effects within the last 30 days of life [17, 18].
Prognostication is often inaccurate despite efforts to improve
it [19]. Over optimism on behalf of the prescribing oncologist
or a failure to discuss realistic survival benefits highlights
Table 2 Quotes from those
patients whose treatment was
stopped
Interview
Toxicity BI regret that I have had to stop the drug because of side-effects,
particularly as there was some evidence it was doing something
helpful to control the growth of my cancer^ (ID 14001 grade II
mouth ulcers and grade II fatigue).
Toxicity BIt’s been horrendous, there have not been any benefits at all, QoL
gone down hugely since I last saw you^ but had no regrets about
taking it BNo regrets as had to try it and would have continued
taking it until I saw the doctor. Didn’t know if it was doing good^
(ID 1021, grade III breathlessness, fatigue, nausea, grade II diarrhoea).
Progression BI feel some regret that I have spent time taking something that made
me ill and didn’t work, it made me worse^
(ID 2016, grade II skin rash, fatigue, and nausea).
Table 3 The responses to the trade-off-type questions at baseline and the 6-week interview
Is (or would) the benefit of the drug in terms of controlling the cancer
be worth (the following grade1 of severity)?
With this grade of side effect, how long do you require the treatment to control
the cancer for you to consider it a worthwhile treatment for you?
N Yes Prob No N At least a month 3 months 6 months At least a year > year
At baseline (prior to or within 2 weeks of starting treatment)
Grade I side effect? 742 95% (70) 4% (3) 1% (13) 72 75% (54) 8% (6) 13% (9) 4% (3)
Grade II side effect? 89 88% (784) 9%
(8)
3% (35) 85 59% (50) 12% (10) 19% (16) 9% (8) 1% (1)
Grade III side effect? 85 44% (376) 15%
(13)
41% (357) 49 49% (24) 16% (8) 22% (11) 10% (5) 2% (1)
At 6 weeks (on treatment)
Grade I side effect? 368–10 97% (35) 1% (1) 3311 79% (26) 6% (2) 9% (3) 6% (2)
Grade II side effect? 66 89% (59) 6% (4) 5% (3) 6212,13 63% (39) 13% (8) 18% (11) 5% (3) 2% (1)
Grade III side effect? 63 52% (33) 13% (8) 35% (22) 4014,15 48% (19) 18% (7) 20% (8) 10% (4) 5% (2)
1 See Appendix for booklet on grades
2 16 who were experiencing moderate side effects were not asked this question
3 The patient who said NO was not asked any further trade-off questions
4 One person who said YES could not respond to the trade-off question
5 Three who responded NO were not asked any further trade-off questions
6 One person who said YES could not respond to the trade-off question
7 35 who responded NO were not asked the trade-off question
8 27 experiencing moderate side effects were not asked the question
9One participant with severe side effects was not asked any trade-off questions
10 Five participants could not answer the question
11 Two participants could not respond to the trade-off question
12 Three who responded NO were not asked the next question
13 One participant who said YES could not answer the trade-off question
14 22 who responded NO were not asked the next question
15 One who said ‘Probably’ could not respond to the trade-off question
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some ethical challenges regarding the veracity of informed
decision-making [20, 21].
Most side effects reported in AVALPROFS occurred
within 2 weeks of starting treatment, and overall, from
the patients’ perspective, fatigue was considered most
bothersome. Although fatigue is a prominent side effect
of systemic anti-cancer therapies, it is also a symptom
of advancing disease and might not be directly treat-
ment related for all patients. A fifth of patients reported
side effects as being worse than anticipated, but those
interviewed at progression, or when stopping drugs due
to toxicity, felt that treatment had nevertheless been
worthwhile. These findings demonstrate the need to
maintain research into ameliorative interventions for
the more common side effects experienced.
Inevitably, attrition will be notable in any longitudinal
study of patients with a poor prognosis. As outlined in our
supplementary material, we have attempted to adjust for this
using a non-parametric-based approach that links the outcome
of interest with the probability of having an observation at a
time point. The adjustments arising from this approach for the
means at each follow-up time point were dramatic, and there-
fore, this same general method of adjustment was used for
regression analyses. The effect of the adjustment is both to
shift estimated effects and to increase the uncertainty
concerning estimation.While it can never be possible to adjust
for attrition completely and definitively, and untestable as-
sumptions must be made in any attempt to do so, we feel that
the presented results in this paper do significantly reduce the
attrition bias that otherwise would have been present.
Few studies have data on whether or not arresting a tu-
mour’s growth brings relief and enhances psychological
well-being. We found that overall emotional well-being in-
creased at 10 weeks but then returned to baseline levels.
This may reflect an initial optimism at being prescribed a
new treatment and then the realisation that life had not im-
proved dramatically or had declined due to the impact of side
effects on QoL.
Patient QoL and well-being need to be considered equally
alongside length of life when exploring patient priorities and
treatment decisions in advanced disease, but concordance be-
tween the severity of side effects reported on patient-reported
outcome measures (PROMs) and those noted by physicians is
rather poor [22, 23]. A recent review showed that although
cancer treatment-related toxicities vary in severity, typically,
only grades 3 and 4 are recorded and reported in clinical trials,
thus diluting recognition of frequency and severity [24]. Part
of the lack of concordance between patients and clinician re-
ports may be the way in which questions are asked; PROMs
such as the FACT-G require patients to indicate over the last
7 days how bothered they have been (not at all, a little, some-
what, verymuch) in response to each item. In contrast, doctors
may be selective and exhibit ascertainment bias by probing
only about expected or most clinically worrying Adverse
Events (AEs) then classifying them on case report forms using
the CTCAE criteria. More accurate data about harms and ben-
efits are nevertheless important to help decision-making when
patients are offered novel therapies that are unlikely to in-
crease survival significantly.
We recognise that the sample size in this study is quite
small; however, it is much larger than many phase I/II cancer
trials examining drug combinations, for example,
bevacizumab and erlotinib (n = 40) [25] or paclitaxel plus
carboplatin and bevacizumab as first-line treatment in triple-
negative metastatic breast cancer (n = 45) [26], neither of
which included QoL assessments.
The authors are aware that this area is an emotive subject,
but patients deserve to have more sensitive discussions about
plausible outcomes from further anti-cancer treatments togeth-
er with less nihilism about supportive care options: if not
Table 4 Quotes in response to
possible grades of side effect Quote
ID 2004; grade I skin rash—left study by
6 weeks with progression
BWith the rash I am hopeful there might be a way to control or live
with it and with it being mild or moderate and the treatment even
gaining me a small amount, a week to a month, is worthwhile you
can do something in that time and something else might come
along. But I think to live with the rash if severe I’d want the
treatment to give decent, min 6 months’ time gain, to be
worthwhile^
ID 1022; grade I mouth soreness—stayed on
treatment
Bfor both the mild and moderate level of mouth soreness side-effect
even a couple of weeks of the treatment controlling things would
make it worthwhile, but for that amount (severe) of side-effect I’d
want a lot of benefit^
ID 3006; grade I nausea—stayed on treatment BOhGod no, if I need help with anything that’s the time that I say no to
everything, if I can’t do what I want to do when I want to do it it’s
not worth living^
ID 2007; grade I itchy skin and nausea—died
within 6 months of study entry
BAny amount of time it gives me longer alive even days is worth it. I
have to do anything I can to stop it (the cancer) growing, I have 3
children (grown up) I want to spend time with and with the
grandchild and hopefully more to come.^
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otherwise, to quote Nicholas Christakis, Bpatients die deaths
they deplore in locations they despise^ [27].
Conclusions
Discussions about disease progression and advantages of
further active treatment in the advanced setting are un-
doubtedly challenging and nuanced. Many factors must
be balanced. The number of patients who either died,
progressed, or withdrew due to toxicity in AVALPROFS
was somewhat disquieting. It is essential that clinicians
retain perspective as to what constitutes meaningful gains
for their patients, namely symptom and/or QoL improve-
ments not just arrest of tumour burden on imaging or tu-
mour marker reductions. We can accept that it is not en-
tirely fair to label what appears to be over-optimistic prog-
nostication as a misreading of published statistical data. It
is true that studies give headline reports of a median PFS
and that applying a population median to an individual will
not always be appropriate. It is also true however that con-
sistently anticipating patients to have responses on the
right side of that median is statistically naive and a belief
that makes gamblers poor. Clinicians need to revisit these
priorities with patients regularly as a treatment protocol is
given since these data show that patient views will change
as treatment is experienced. We also need more effective
ameliorative interventions to help patients who experience
the common class effects of many novel drugs in particular
for fatigue and diarrhoea. Finally, oncologists who un-
doubtedly care deeply about their patients need to develop
an acute awareness of the fact that in their desire to main-
tain patients’ hope, they may be as overly optimistic about
the putative benefits of many novel drugs offering only
PFS, as are their patients.
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